MAPT and Alzheimer disease: The results of a meta-analysis of blood biomarkers showed increased t-tau, p-tau 181, p-tau 217, neurofilament light protein (NFL) and decreased Aβ1–42 in patients with AD and AD-MCI (Qu et al., 2021).